Sensorion Financials Overview

Stocks . France . 
Stock . Sensorion SA
ALSEN Stock  EUR 0.43  0.02  4.88%   
Sensorion's profitability, debt capacity, and cash conversion metrics provide the foundation for assessing financial durability. On the balance sheet, cash sits at $26.79 million with debt at $1.23 million. The income statement, balance sheet, and cash-flow statement each capture a different dimension of the business. Reviewing balance sheet structure and operating performance, Sensorion SA appears to maintain pressured financial positioning. Profitability remains under pressure, with return on assets below breakeven in the current period.

Sensorion Stock Summary

Sensorion is commonly compared to Mediantechn, Maat Pharma, Innate Pharma, OSE Pharma, and Crossject. Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. The company was founded in 2009 and is headquartered in Montpellier, France. SENSORION operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 33 people.
InstrumentFrance Stock View All
ExchangeEuronext Paris
ISINFR0012596468
Business Address375, rue du
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.sensorion.com
Phone33 4 67 20 77 30
Trading CurrencyEUR - Euro
Revenue, margins, and capital structure at Sensorion are presented below from the most recent reporting periods. Line items are grouped by statement so that leverage, margin compression, and cash burn - if present - surface independently. The trajectory of these line items determines whether Sensorion SA competitive position is improving or eroding.
Reviewing Sensorion Stock's financial statements provides foundational context for evaluating the investment. Well-informed analysis of Sensorion Stock typically begins with independent review of the data. Investors who read Sensorion's financial statements directly are better able to spot risks and chances.

Key Financial Ratios

Sensorion's key ratios measure how effectively revenue converts to profit, how sustainably debt supports the capital structure, and how efficiently assets generate returns.

Financial Ratio Analysis

Financial Metrics, Fundamentals & Methodology

Balance-sheet positioning at Sensorion helps frame liquidity flexibility across changing market conditions. Return on equity helps show how effectively management is turning capital into earnings. In recent filings, Sensorion reported EPS loss of 0.1, negative operating margin of 4.0%, current ratio of 13.47 as of the latest reporting period.

Sensorion SA inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Statement-level metrics reflect company-reported GAAP or IFRS formats for the relevant filing period.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors

Additional Tools for Sensorion Stock Analysis

Positions RatingsView algorithmic ratings for individual portfolio positions based on fundamental analysis and risk-adjusted market performanceEquity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunitiesStock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.Money ManagersScreen money managers from public funds and ETFs managed around the worldCompetition AnalyzerCompare fundamental indicators side by side for a group of related or unrelated entitiesFundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunitiesPortfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfoliosStock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websitesPrice TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.